Nipple-Sparing Mastectomy in BRCA1/2 Mutation Carriers: An Interim Analysis and Review of the Literature

Yao, Katharine; Liederbach, Erik; Tang, Rong; Lan, Lei; Czechura, Tomasz; Sisco, Mark; Howard, Michael A.; Hulick, Peter J.; Weissman, Scott M.; Winchester, David J.; Coopey, Suzanne B.; Smith, Barbara L.

doi:10.1245/s10434-014-3883-3

Cited by 107 publications

(78 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, nipple-sparing mastectomy has not shown any additional cancer risk in this patient population (44), but patients require lifelong screening and should be counseled accordingly prior to surgery (40). Bilateral salpingo-oophorectomy reduces the risk of ovarian cancer by 83% and combined with bilateral mastectomies reduces the risk of breast cancer by 95% (43,45).…”

Section: Genetic Basis For Treatmentmentioning

confidence: 96%

Integrating surgery and genetic testing for the modern surgeon

Caso¹,

Beamer²,

Lofthus³

et al. 2017

Annals of Translational Medicine

View full text Add to dashboard Cite

The field of cancer genetics is rapidly evolving and several genetic mutations have been identified in hereditary cancer syndromes. These mutations can be diagnosed via routine genetic testing allowing prompt intervention. This is especially true for certain variants of colorectal, breast, and thyroid cancers where genetic testing may guide surgical therapy. Ultimately, surgical intervention may drastically diminish disease manifestation or progression in individuals deemed as high-risk based on their genetic makeup.Understanding the concepts of gene-based testing and integrating into current surgical practice is crucial.This review addresses common genetic syndromes, tests, and interventions salient to the current surgeon.

show abstract

Section: Genetic Basis For Treatmentmentioning

confidence: 96%

Integrating surgery and genetic testing for the modern surgeon

Caso¹,

Beamer²,

Lofthus³

et al. 2017

Annals of Translational Medicine

View full text Add to dashboard Cite

show abstract

“…4 While many surgeons offer the procedure to women with more advanced disease, there is agreement that the nipple margin needs to be evaluated separately and the location indicated to the pathologist. In the series by Yao et al 1 three of the 51 patients (1.5 %) undergoing therapeutic NSM were found to have disease at the nipple margin. No positive nipple margins were seen in the prophylactic group.…”

mentioning

confidence: 95%

“…1 This retrospective study adds to a growing body of literature supporting the safety of NSM in general, but it is especially valuable due to its focus on women with BRCA mutations, on whom there is limited data. This study is also unique in that it includes these highrisk women undergoing NSM for cancer treatment (n = 51, 25%) in addition to women undergoing prophylactic surgery only (n = 150, 75%).…”

mentioning

confidence: 99%

“…Yao et al nicely summarize the available data regarding nipple recurrence in Table 4 of their article. 1 Large series of NSM have now been reported, with low rates of cancer recurrence overall and with NAC recurrences occurring only rarely. Indeed, of the over 3,000 patients included in Table 4, less than 1 % developed disease in the retained NAC.…”

mentioning

confidence: 99%

“…As surgeons become more comfortable with the procedure and eligibility is expanded to include more patients, 1,5 it is important to note that there is a learning curve to this procedure. A skin-sparing mastectomy is often technically challenging given the small incision size, need to access the axilla, and given competing demands of removing all breast tissue but maintaining perfusion of the skin flap.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Safely Expanding the Use of Nipple-Sparing Mastectomy in BRCA Mutation Carriers

Cyr¹

2014

Ann Surg Oncol

View full text Add to dashboard Cite

This past year, I presented data supporting the safety of nipple-sparing mastectomy (NSM) to a Latin American audience. After the talk, one of the participants thanked me for the talk but she was disheartened that the local medical oncologist described my presentation to his colleagues as nothing less than blasphemy. Although recently more accepting of NSM, our medical community also questions the oncologic safety of NSM. Should it be limited to prophylactic procedures? Is it safe for women with more advanced disease or with BRCA mutations?Women with BRCA mutations have a significant lifetime risk of developing breast cancer, and it is wellestablished that prophylactic mastectomy significantly reduces that risk. For BRCA mutation carriers diagnosed with cancer, bilateral mastectomies are typically performed due to the high risk of second breast cancer events. Many of these women are young at the time of surgery but, regardless of age, improving cosmetic results with reconstruction make this aggressive surgery more palatable. NSM can successfully reduce cancer risk and it also offers an improved cosmetic outcome with reconstruction; a woman's native nipple is typically cosmetically superior to a reconstructed nipple. However, the high breast cancer risk associated with a BRCA mutation mandates that the surgery be as effective as possible at reducing future breast cancer events.In the article that accompanies this editorial, Yao et al. report on a series of 397 NSMs performed at two different institutions on 201 women with documented BRCA1 and BRCA2 mutations.1 This retrospective study adds to a growing body of literature supporting the safety of NSM in general, but it is especially valuable due to its focus on women with BRCA mutations, on whom there is limited data. This study is also unique in that it includes these highrisk women undergoing NSM for cancer treatment (n = 51, 25%) in addition to women undergoing prophylactic surgery only (n = 150, 75%). In order to answer the question of whether NSM is safe for women with BRCA mutations, it is important to first define the procedure, and to contrast it to subcutaneous mastectomy, which is not an oncologic procedure. During a subcutaneous mastectomy, a thick skin flap (and therefore breast tissue) is left behind with the nipple and areolar complex (NAC). Despite the intentional retention of some breast tissue, prophylactic subcutaneous mastectomies have actually been associated with low rates of subsequent cancer.2 However, a modern NSM aims to remove as much breast parenchyma as possible, up to the base of the nipple and often including a core of tissue within the nipple. Done appropriately, the NSM only differs from the now wellaccepted skin-sparing mastectomy in the preservation of the areolar skin and the skin of the nipple.If the NAC is retained, how often is this tissue involved with cancer recurrence or with new cancer development? Yao et al. nicely summarize the available data regarding nipple recurrence in Table 4 of their article.1 Large series of NSM h...

show abstract